Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Sep 2019 Planned number of patients changed from 277 to 203.
- 03 Sep 2019 Planned End Date changed from 1 May 2023 to 1 Feb 2024.
- 03 Sep 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2021.